Merck & Co., Inc. (NYSE: MRK) ended Friday, December 12, 2025, at $100.30, climbing 1.30% on the day and finishing slightly higher for the week after a choppy stretch driven by vaccine-policy headlines and scrutiny around RSV preventive therapies. [1]
Below is a detailed, Google News/Discover–ready look at what moved Merck stock this week, what the latest company and sector headlines mean for MRK, what analysts are forecasting, and what investors are watching in the week ahead.
Merck stock performance this week: A late rebound after early pressure
Closing price (Dec. 12): $100.30.
MRK’s weekly story was less about a single “headline spike” and more about a two-part move:
- Early-week dip (Dec. 8–9): MRK slid from $98.93 (Mon.) to $96.89 (Tue.). [2]
- Three-day rebound (Dec. 10–12): Shares then rose three sessions in a row, closing $97.62 (Wed.), $99.01 (Thu.), and $100.30 (Fri.). [3]
Net-net, MRK finished up about 0.6% versus the prior Friday close ($99.72 on Dec. 5 to $100.30 on Dec. 12). [4]
On Friday, MRK’s gain came even as major indexes were weak (MarketWatch reported the S&P 500 fell 1.07% and the Dow fell 0.51% that session), which helped MRK look like a defensive “quality bid” into the close. [5]
Key technical context: MarketWatch noted MRK remained 5.23% below its 52-week high of $105.84 (set Nov. 25), and Friday volume was about 11.8 million shares, below the 50‑day average. [6]
The biggest MRK headlines from the last several days
1) Winrevair gets a positive EU CHMP opinion for expanded use (Dec. 12)
Merck said it received a positive opinion from the European Medicines Agency’s CHMP recommending expanded use of WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH, WHO Group 1). Merck added that a European Commission decision is expected in Q1 2026. [7]
Why this mattered: Merck pointed to Phase 3 ZENITH data showing a 76% reduction in risk of major morbidity/mortality outcomes (hazard ratio 0.24, p<0.0001), and the trial was stopped early at interim analysis for “overwhelming efficacy.” [8]
Stock read-through: Winrevair is one of Merck’s most closely watched growth engines outside oncology. A favorable EU regulatory trajectory can support the “post-Keytruda” growth narrative that many analysts want to see continue into 2026.
2) FDA launches fresh safety scrutiny of RSV preventive therapies for infants (Dec. 9)
Reuters reported U.S. regulators notified senior executives at Merck, Sanofi, and AstraZeneca that their RSV preventive products for infants would face fresh safety scrutiny, including Merck’s Enflonsia. [9]
Important details from the Reuters report:
- The review comes amid heightened attention from vaccine skeptics and broader reevaluation of parts of U.S. vaccine policy. [10]
- Reuters said Merck confirmed the FDA meeting and said it welcomed continued scientific dialogue, adding it was confident in Enflonsia’s safety. [11]
- Reuters also cited sales context: Sanofi’s Beyfortus generated more than $2.6B in 2024 global sales, while Merck’s newer Enflonsia was expected to make about $250M next year. [12]
Stock read-through: This headline helped explain the sharp down day on Tuesday (Dec. 9). While Reuters emphasized it was unclear whether FDA would change labeling or restrict availability, the risk for MRK investors is that a “routine review” becomes a longer policy-driven overhang. [13]
3) U.S. hepatitis B newborn-shot recommendation rollback adds vaccine-policy uncertainty (Dec. 5–7)
Reuters reported the vaccine-policy backdrop shifting in a way that has direct relevance for Merck’s vaccine portfolio. In one Reuters story, Merck said it was “deeply concerned” about a move away from the long-standing universal hepatitis B birth dose recommendation, urging evidence-based decision-making. [14]
A separate Reuters piece described experts warning that the new recommendation “turned back the clock” on disease prevention and could reverse progress from universal newborn vaccination. [15]
Stock read-through: For MRK, this isn’t just a single product question—it’s a signal that U.S. vaccine policy (and related advisory processes) may stay a volatility driver. When investors can’t handicap the policy pathway, they typically demand a higher risk premium—especially for companies with meaningful vaccine exposure.
4) Keytruda SC setback in Germany tied to Halozyme patent dispute (Dec. 4)
STAT reported a German court issued a preliminary injunction preventing Merck from distributing a subcutaneous formulation of Keytruda in Germany, tied to a patent dispute involving Halozyme; the IV version was described as not affected. [16]
Halozyme also announced (via PRNewswire) it had won a preliminary injunction regarding Keytruda SC in Germany. [17]
Stock read-through: Investors generally view Keytruda delivery innovations (including more convenient administration) as part of Merck’s strategy to defend oncology leadership. Even if geographically limited, injunctions can be read as a reminder that patents and lifecycle-management remain a headline risk around Merck’s biggest franchise.
5) Merck Animal Health: FDA conditional approval for Exzolt in cattle (Dec. 2025)
Merck Animal Health said the FDA granted conditional approval for Exzolt (fluralaner oral solution) for cattle, aimed at killing New World screwworm larvae, and that the product is expected to be available in Q1 2026. [18]
Stock read-through: Animal Health is typically not the “headline mover” that oncology is, but it’s an important stabilizer for Merck’s revenue mix—and incremental approvals reinforce that the segment continues to innovate.
Analyst forecasts and Wall Street positioning: Still broadly constructive
Across the sell-side, the posture on Merck remains generally bullish, even as investors debate how smoothly Merck can navigate the Keytruda patent horizon and near-term policy noise.
Consensus rating and price targets
Benzinga’s analyst aggregation showed:
- Consensus rating: “Buy”
- Consensus price target:$117.93
- Range:$85 (low) to $155 (high) [19]
Recent analyst moves (late Nov through Dec. 12)
StockAnalysis’ analyst table lists several notable recent changes:
- Morgan Stanley: maintained Hold, raised target $100 → $102 (Dec. 12) [20]
- Scotiabank: maintained Buy, raised target $105 → $120 (Dec. 4) [21]
- Goldman Sachs: maintained Strong Buy, raised target $92 → $120 (Dec. 2) [22]
- Wells Fargo: upgraded Hold → Buy, raised target $90 → $125 (Nov. 24) [23]
What this suggests: The recent cluster of target increases into early December indicates that several major desks believe Merck’s 2026 setup (pipeline + diversification) is improving enough to justify higher valuation—even as the tape reacts to policy-driven vaccine headlines.
What fundamentals analysts are watching: growth beyond Keytruda
Merck’s central long-term investing question remains simple: How successfully can the company diversify growth away from Keytruda over time—without losing the cash-generation engine that funds R&D, dividends, and dealmaking?
Street estimates (as a snapshot)
StockAnalysis’ consensus-style forecast page lists:
- Revenue: about $65.43B for FY2025 and $68.68B for FY2026
- EPS: about 9.06 (FY2025) and 9.49 (FY2026) [24]
These are not company guidance; they’re aggregated estimates—but they frame why some analysts are comfortable lifting targets: the baseline narrative is still modest revenue growth with earnings resilience.
Merck’s “next leg” catalysts investors cite most often
Based on this week’s headlines, the market’s focus is clustering around three buckets:
- Cardiopulmonary growth (Winrevair): A positive EU CHMP opinion adds momentum to a product many investors see as a major non-oncology growth driver. [25]
- Vaccines/RSV policy risk: FDA scrutiny of RSV infant antibodies and shifting hepatitis B guidance creates uncertainty for the category. [26]
- Oncology lifecycle defense: Keytruda formulation disputes highlight the importance of administration convenience and patent strategy. [27]
Dividend watch: a near-term catalyst for income-focused holders
MRK’s next ex-dividend date is Dec. 15, 2025, with the next payment shown as Jan. 8, 2026 on Dividend.com’s listing. [28]
Why it matters for the week ahead: Dividend timing can affect short-term flows (especially for funds and dividend-focused mandates). It’s not usually a fundamental catalyst, but it can influence Monday/Tuesday price action around the ex-date.
Week-ahead outlook: what could move MRK next week
Here are the most practical MRK “watch items” for the coming week (Dec. 15–19, 2025):
1) Ex-dividend day (Dec. 15)
The ex-date is the most concrete, calendar-driven item for MRK in the immediate week ahead. [29]
2) Macro: November CPI release (Dec. 18, 8:30 a.m. ET)
The U.S. Bureau of Labor Statistics schedule shows November 2025 CPI is due Dec. 18, 2025 at 8:30 a.m. [30]
For Merck, CPI matters less because “drug inflation” doesn’t map cleanly onto consumer inflation, but CPI can still move:
- Treasury yields
- defensive vs. cyclical rotations
- large-cap healthcare multiples
3) Continued vaccine-policy volatility risk
After Reuters’ reporting on hepatitis B guidance changes and vaccine-policy upheaval, investors will watch for follow-on signals (CDC adoption steps, additional advisory discussions, or further scrutiny of childhood immunization recommendations). [31]
4) Any incremental updates on RSV review scope
Reuters emphasized uncertainty around whether FDA will take actions affecting labeling or availability for RSV preventive therapies. Any clarity—requested data, timelines, advisory committee discussion—could move sentiment quickly. [32]
5) Investor calendar: next earnings date is further out, but known
Merck’s investor relations calendar lists the Q4 2025 earnings call on Feb. 3, 2026. [33]
That’s not a “next week” event, but it’s the next major scheduled fundamental checkpoint.
Bottom line for MRK stock: constructive long-term narrative, noisy short-term tape
Merck stock closed this week back above $100 after digesting a burst of policy and regulatory headlines. The bull case is getting tangible support from product momentum (Winrevair’s EU progress being the latest example), plus a steady dividend profile and large-cap defensiveness. [34]
The bear case—at least in the short run—is that vaccine-policy uncertainty and FDA scrutiny around RSV products create an unpredictable headline stream that can pressure sentiment even if underlying product safety/efficacy data remains strong.
For the week ahead, the most immediate “known dates” are MRK’s Dec. 15 ex-dividend and the Dec. 18 CPI release—but the real volatility risk is whether the vaccine-policy story continues to expand into additional products or processes. [35]
References
1. stockanalysis.com, 2. stockanalysis.com, 3. stockanalysis.com, 4. stockanalysis.com, 5. www.marketwatch.com, 6. www.marketwatch.com, 7. www.merck.com, 8. www.merck.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.reuters.com, 13. www.reuters.com, 14. www.reuters.com, 15. www.reuters.com, 16. www.statnews.com, 17. www.prnewswire.com, 18. www.merck.com, 19. www.benzinga.com, 20. stockanalysis.com, 21. stockanalysis.com, 22. stockanalysis.com, 23. stockanalysis.com, 24. stockanalysis.com, 25. www.merck.com, 26. www.reuters.com, 27. www.statnews.com, 28. www.dividend.com, 29. www.dividend.com, 30. www.bls.gov, 31. www.reuters.com, 32. www.reuters.com, 33. www.merck.com, 34. www.merck.com, 35. www.dividend.com
